Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET Scan for Cancer
Recruiting1 award7 criteria
Duarte, California
This trial uses a radioactive antibody to help detect cancer cells in patients with high levels of a protein called CEA. PET scans may help find and diagnose cancer that may not be detected by other methods.
Radiotherapy
Contrast-Enhanced Ultrasound for Bile Duct Cancer
Recruiting3 awardsPhase 2
Philadelphia, Pennsylvania
This trial is testing whether a type of ultrasound that uses gas microbubbles can predict how well bile duct cancer will respond to targeted radiotherapy. The ultrasound may also help doctors see if microbubble popping can improve bile duct cancer response to radiotherapy.
Anti-tumor antibiotic
TAS-102 + Nanoliposomal Irinotecan for Gastrointestinal Cancer
Recruiting1 awardPhase 1 & 2
Atlanta, Georgia
This trial is studying the best dose and how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) and nanoliposomal irinotecan work in treating patients with gastrointestinal cancers that have spread to other places in the body (metastatic) or cannot be removed by surgery.
Monoclonal Antibodies
Guadecitabine + Durvalumab for Liver and Pancreatic Cancer
Recruiting1 awardPhase 1
Los Angeles, California
This trial is testing the side effects and best dosage of a new cancer drug, guadecitabine, when given with another drug, durvalumab. Guadecitabine works by blocking enzymes needed for cell growth, and durvalumab works by targeting certain cells. The hope is that the two drugs will work better together than either does alone in treating liver, pancreatic, bile duct, or gallbladder cancer.
Popular Filters
Trials for Cholangiocarcinoma Patients
Alkylating Agent
BAY 1895344 + Chemotherapy for Bladder Cancer
Recruiting1 awardPhase 1
Sacramento, California
This trial tests a new drug, BAY 1895344, combined with chemotherapy to treat advanced cancers. It aims to find the best dose and check for side effects. The treatment works by blocking enzymes needed for tumor growth and killing cancer cells. The trial focuses on patients with advanced solid tumors or urothelial cancer.
Trials for EBD Cancer Patients
Alkylating Agent
BAY 1895344 + Chemotherapy for Bladder Cancer
Recruiting1 awardPhase 1
Sacramento, California
This trial tests a new drug, BAY 1895344, combined with chemotherapy to treat advanced cancers. It aims to find the best dose and check for side effects. The treatment works by blocking enzymes needed for tumor growth and killing cancer cells. The trial focuses on patients with advanced solid tumors or urothelial cancer.
Trials for Metastatic Patients
Monoclonal Antibodies
DB-1303 for Solid Cancers
Recruiting1 awardPhase 1 & 2
Whittier, California
This trial is testing a new drug called DB-1303 to see if it is safe for patients with advanced solid tumors that express HER2. The study will begin with lower doses and increase them over time to find the highest dose that patients can handle. This helps determine the best dose for future studies.
Alkylating Agent
BAY 1895344 + Chemotherapy for Bladder Cancer
Recruiting1 awardPhase 1
Sacramento, California
This trial tests a new drug, BAY 1895344, combined with chemotherapy to treat advanced cancers. It aims to find the best dose and check for side effects. The treatment works by blocking enzymes needed for tumor growth and killing cancer cells. The trial focuses on patients with advanced solid tumors or urothelial cancer.
Trials for FGFR2 Positive Patients
Alkylating agents
Pemigatinib vs Chemotherapy for Bile Duct Cancer
Recruiting2 awardsPhase 3
Phoenix, Arizona
This trial is testing a new drug called pemigatinib against the usual cancer treatment. It focuses on patients with advanced bile duct cancer who have a specific change in their genes. The goal is to see if pemigatinib is more effective and safer than the usual treatment. Pemigatinib is the first of its kind approved in the US, receiving approval recently.
Tyrosine Kinase Inhibitor
RLY-4008 for Bile Duct Cancer
Recruiting1 awardPhase 1 & 2
Phoenix, Arizona
This trial is testing a new drug called RLY-4008 in patients with hard-to-treat cancers that can't be removed by surgery or have spread. The drug works by blocking a protein that helps cancer cells grow.
Tyrosine Kinase Inhibitor
Afatinib + Pemigatinib for Solid Tumors
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is testing if a combination of two drugs, Afatinib and Pemigatinib, is safe and effective for treating certain types of advanced solid tumors with specific genetic mutations. The study
FGFR Inhibitor
Tinengotinib for Bile Duct Cancer
Recruiting2 awardsPhase 3
Santa Monica, California
This trial is testing an oral medication called Tinengotinib for patients with a specific type of bile duct cancer that has not responded to other treatments. The medication works by blocking a protein that helps cancer cells grow. The goal is to see if Tinengotinib can slow down or stop the cancer in these patients.
Phase 3 Trials
Alkylating agents
Pemigatinib vs Chemotherapy for Bile Duct Cancer
Recruiting2 awardsPhase 3
Phoenix, Arizona
This trial is testing a new drug called pemigatinib against the usual cancer treatment. It focuses on patients with advanced bile duct cancer who have a specific change in their genes. The goal is to see if pemigatinib is more effective and safer than the usual treatment. Pemigatinib is the first of its kind approved in the US, receiving approval recently.
Anti-microtubule agent
CTX-009 + Paclitaxel for Biliary Tract Cancer
Recruiting1 awardPhase 2 & 3
Albuquerque, New Mexico
This trial tests a new drug (CTX-009) combined with chemotherapy in patients with advanced biliary tract cancers who have already had other treatments and cannot have surgery. The treatment aims to boost the immune system and stop cancer cell growth.
Monoclonal Antibodies
Atezolizumab + Bevacizumab for Gastrointestinal Cancer
Recruiting2 awardsPhase 3
Washington, District of Columbia
This trial will enroll 20 patients with gastrointestinal cancers who have completed all standard treatments but still have evidence of the disease. Patients will receive intravenous atezolizumab and bevacizumab once every 21 days for a maximum of 12 months.
FGFR Inhibitor
Tinengotinib for Bile Duct Cancer
Recruiting2 awardsPhase 3
Santa Monica, California
This trial is testing an oral medication called Tinengotinib for patients with a specific type of bile duct cancer that has not responded to other treatments. The medication works by blocking a protein that helps cancer cells grow. The goal is to see if Tinengotinib can slow down or stop the cancer in these patients.
Trials With No Placebo
Monoclonal Antibodies
DB-1303 for Solid Cancers
Recruiting1 awardPhase 1 & 2
Whittier, California
This trial is testing a new drug called DB-1303 to see if it is safe for patients with advanced solid tumors that express HER2. The study will begin with lower doses and increase them over time to find the highest dose that patients can handle. This helps determine the best dose for future studies.
Alkylating Agent
BAY 1895344 + Chemotherapy for Bladder Cancer
Recruiting1 awardPhase 1
Sacramento, California
This trial tests a new drug, BAY 1895344, combined with chemotherapy to treat advanced cancers. It aims to find the best dose and check for side effects. The treatment works by blocking enzymes needed for tumor growth and killing cancer cells. The trial focuses on patients with advanced solid tumors or urothelial cancer.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.